IP36: Bladder Cancer: Invasive I
Saturday, May 16, 2026 9:30 AM to 11:30 AM · 2 hr. (America/New_York)
147B
Poster and Podium Sessions
Oncology: Bladder
Saturday, May 16
IP36-01: RBMX-mediated ac4C Modification of PD-L1 mRNA Drives RC48 Resistance in HER2-Positive Bladder Cancer by Fostering an Immunosuppressive Microenvironment
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-02: Comparable Prognostic Utility of Circulating Tumor DNA in Patients with Pure and Variant Histology Bladder Cancer Undergoing Radical Cystectomy
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-03: CDK4/6 Inhibition Induces Fibroblast-Mediated CD8+ T Cell Trafficking in Muscle-Invasive Bladder Cancer (MIBC): Mechanistic Rationale for Sequential Therapy with Enfortumab Vedotin-Pembrolizumab (EV-P)
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-04: Integrative Clinical and Molecular Characterization of Metastasis and Resistance to Antibody-Drug Conjugates in Sarcomatoid Variant Bladder Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-05: Molecular differences in locally advanced and metastatic urothelial carcinoma patients of different socioeconomic backgrounds
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-06: Association of genomic disease burden markers and programmed death-ligand 1 with clinical outcomes in patients with muscle-invasive bladder cancer treated with gemcitabine intravesical system + cetrelimab (CET) or CET alone in the Phase 2 SunRISe
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-07: Development of a Transcriptome-Based Model for Predicting Adverse Pathology at Radical Cystectomy
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-08: Trends in Complete Response After Radical Cystectomy Without Neoadjuvant Immunotherapy: Is Chemotherapy the Real Driver of Pathological Complete Response?
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-09: Evaluating the Surrogacy of Intermediate Clinical Endpoints for Overall Survival after Perioperative Treatment in Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-10: Real-World Outcomes of Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma Ineligible for Clinical Trials
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-11: Are Traditional Treatment Approaches Outdated in Metastatic Urothelial Carcinoma? A Comparative Evaluation by First-line Cisplatin Use and Treatment Era
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-12: Bayesian re-analysis of the NIAGARA trial using reconstructed individual patient data: early event-free survival gains with perioperative durvalumab in muscle-invasive bladder cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-13: Adding upfront, perioperative durvalumab versus adopting risk-adapted adjuvant nivolumab? Cost-effectiveness analysis of competing treatment strategies for cisplatin-eligible muscle-invasive bladder cancer in the era of immune checkpoint inhibito
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-14: Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-15: The impact of manual vs stapler sewn ileoileal anastomosis on the incidence and the management of the postoperative complications in patients underwent radical cystectomy with ileal conduit: a randomized prospective single center trial (PUMA tria
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-16: Beyond Glycemic Control and Obesity: Are GLP-1 Agonists Associated with Fewer Metabolic and Acid–Base Disorders After Radical Cystectomy?
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-17: Long-term survivors after radical cystectomy: insight on clinical and pathological characteristics on survival and their effect over time
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-18: 10-year Urothelial Fellowship in Robotic-assisted Radical Cystectomy and Intracorporeal Ileal Conduit (RARC/ICIC) Urinary Diversion: Trends in Surgical Practice, Perioperative Outcomes, and Predictors of Surgical Modular Competency
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-19: Lymphovascular invasion and nodal positivity as useful markers for selecting candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
Hiroki Shimoda · Cancer Institute Hospital, Japanese Foundation for Cancer research
IP36-20: Homozygosity of Killer Immunoglobulin-Like Receptors A Haplotype Is Associated With Clinical Outcomes in Patients With Urothelial Cancer Treated With Pembrolizumab
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-21: Survival after Induction Chemotherapy and Radical Cystectomy in cN+/pN+ M0 Bladder Cancer: Implications for pretreatment patient selection
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-22: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-23: Association Between Hyperphosphatemia and Survival in FGFR-Altered Urothelial Cancer Treated With Erdafitinib: A Post Hoc Analysis of the THOR Phase III Randomized Clinical Trial
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-25: Long-Term Oncologic Outcomes and Extracellular Vesicle Signatures in Bladder Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-26: Awareness of genetic risk of Bladder Cancer associated to germline variants in DNA-repair genes (gDRGs) in Caucasian ancestry families
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-27: Novel T cell signature based on cell pair algorithm predicts survival and immunotherapy response for patients with bladder urothelial carcinoma
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-28: Increased frequency of neoadjuvant chemotherapy in muscle-invasive bladder cancer after the introduction of adjuvant immunotherapy
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-29: The impact of en-bloc resection of tumor technique on histopathological outcomes, subsequent management, and early recurrence in newly diagnosed bladder cancer: A retrospective analysis of single-institution experience
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
IP36-30: Differences in Patient-Reported and Objective Functional Recovery Trajectories Following Radical Cystectomy: Findings from the UW Prospective Bounceback Cohort Study
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147B
